Nisa Investment Advisors
ANTX icon

Nisa Investment Advisors’s AN2 Therapeutics ANTX Stock Holding History

Nisa Investment Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed – – 2803
2023
Q1 		$0 Hold
10
– – ﹤0.01% 2521
2022
Q4 		$0 Buy
+10
New +$134 ﹤0.01% 2576

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Nisa Investment Advisors's ANTX Position: Q2 2023 in Review

Nisa Investment Advisors sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 10 shares.

Nisa Investment Advisors first reported a position in ANTX in Q4 2022 and held it in 2 quarters. The position peaked at $0 in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

  • Nisa Investment Advisors reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 10 AN2 Therapeutics shares in Q2 2023.
  • Nisa Investment Advisors first reported a position in AN2 Therapeutics in Q4 2022 and held it in 2 quarters.
  • Nisa Investment Advisors's AN2 Therapeutics position peaked at $0 in Q1 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.